ARS Pharmaceuticals’ (SPRY) “Outperform” Rating Reaffirmed at William Blair

William Blair reaffirmed their outperform rating on shares of ARS Pharmaceuticals (NASDAQ:SPRY) in a research report report published on Monday morning,RTT News reports.

Other analysts also recently issued reports about the company. Oppenheimer assumed coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective for the company. Raymond James lifted their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Finally, Leerink Partners lifted their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $28.80.

ARS Pharmaceuticals Trading Down 2.9 %

NASDAQ:SPRY opened at $10.18 on Monday. The stock has a fifty day simple moving average of $11.91 and a 200-day simple moving average of $13.21. The company has a market cap of $989.34 million, a price-to-earnings ratio of -19.96 and a beta of 0.99. ARS Pharmaceuticals has a twelve month low of $7.55 and a twelve month high of $18.51.

Insiders Place Their Bets

In other news, insider Sarina Tanimoto sold 100,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total transaction of $1,316,000.00. Following the sale, the insider now owns 1,148,499 shares in the company, valued at approximately $15,114,246.84. The trade was a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Shawver sold 50,000 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $11.10, for a total value of $555,000.00. Following the sale, the director now owns 210,346 shares in the company, valued at $2,334,840.60. The trade was a 19.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 417,044 shares of company stock worth $5,204,515. 40.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Bernard Wealth Management Corp. purchased a new stake in shares of ARS Pharmaceuticals during the fourth quarter worth about $27,000. Ball & Co Wealth Management Inc. purchased a new stake in shares of ARS Pharmaceuticals during the fourth quarter worth about $105,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of ARS Pharmaceuticals by 5.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 247,314 shares of the company’s stock worth $2,609,000 after acquiring an additional 12,777 shares during the last quarter. Woodline Partners LP grew its stake in shares of ARS Pharmaceuticals by 13.5% during the fourth quarter. Woodline Partners LP now owns 1,119,283 shares of the company’s stock worth $11,808,000 after acquiring an additional 133,276 shares during the last quarter. Finally, Wexford Capital LP grew its stake in shares of ARS Pharmaceuticals by 48.8% during the fourth quarter. Wexford Capital LP now owns 369,497 shares of the company’s stock worth $3,898,000 after acquiring an additional 121,150 shares during the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.